Urological Devices – Market Insights – United States

Fueled by product innovation, rising kidney stone prevalence, and an aging population, the US market for urological devices will grow at a moderate rate through 2033, driven particularly by rising revenues for BPH devices—especially Aquablation—single-use endoscopes, and UI devices. Other contributing factors for growth include an increasing prevalence of obesity, the adoption of premium devices, and the growing availability of less-invasive treatment options.

This Medtech 360 Report provides comprehensive data and analysis on the state of the US urological device market from 2019 through 2033.

Single-use endoscopes have been rapidly gaining adoption.

Which are the biggest competitors in the single-use endoscopy market?

How do the device sales of these devices compare with that of conventional reusable counterparts?

What are the advantages of these devices?

Minimally invasive treatment volumes will grow strongly.

What factors contribute to the increase of minimally invasive treatments?

How have minimally invasive treatment options changed the BPH device market?

Which market segments will see the greatest adoption of minimally invasive treatments?

What is the impact of Aquablation on the US urological device market?

Mergers and acquisitions have been altering the competitive landscape.

What are the most relevant recent acquisitions to affect the market?

How will market shares and product portfolios be affected as a result of these acquisitions?

Ongoing clinical studies and research continue to affect procedure trends, and thus device trends.

What do recent studies indicate regarding the outlook of existing techniques for treating prostate cancer, kidney stones, and BPH?

What upcoming novel treatments are expected to compete with existing methods of treatment?